{"classes":[{"categories":[{"measurements":[{"comment":"N/A = Median OS was non-estimable for patients with laBCC receiving treatment with sonidegib 200 mg as limited number of deaths were observed.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A = Median OS was non-estimable for patients with laBCC receiving treatment with sonidegib 800 mg as limited number of deaths were observed.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A = Both lower and upper confidence intervals were not estimable as limited number of deaths were observed.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"47.6"},{"comment":"N/A = Both lower and upper confidence intervals were not estimable as limited number of deaths were observed.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"33.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"OS is defined as the time from date of randomization to date of death due to any cause or the last date that a patient was known to be alive (censored observation) as of the data cut-off.","dispersionType":"95% Confidence Interval","groups":[{"description":"The efficacy and safety of LDE225 200mg laBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG000","title":"LDE225 200mg laBCC"},{"description":"The efficacy and safety of LDE225 800mg laBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG001","title":"LDE225 800mg laBCC"},{"description":"The efficacy and safety of LDE225 200mg mBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG002","title":"LDE225 200mg mBCC"},{"description":"The efficacy and safety of LDE225 800mg mBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG003","title":"LDE225 800mg mBCC"}],"paramType":"MEDIAN","populationDescription":"The full analysis set (FAS) comprised all patients who were assigned study treatment irrespective of receiving it (all randomized patients). Patients were classified according to the treatment they were assigned in accordance with the intention-to-treat (ITT) principle.","reportingStatus":"POSTED","timeFrame":"42 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}